Genomind Presents At 2011 NAMI Convention On Emerging Technologies To Improve Care

Genomind Presents At 2011 NAMI Convention On Emerging Technologies To Improve Care

July 8, 2011 – Chicago, Illinois – Genomind, LLC (www.genomind.com) presented today at the 2011 NAMI (National Alliance on Mental Illness) Convention during the session “Emerging Technologies to Improve Care.” Moderated by Kenneth M. Duckworth, MD, Medical Director for NAMI, Genomind will discuss the advent of personalized medicine and the use of biomarkers in psychiatry and mental health. Its Genecept™ Assay, an example of the use of biomarkers, combines proprietary genetic tests, an analytic report, and psychopharmacologist support for clinicians who see patients with treatment resistant conditions.

“We support NAMI’s interest in bringing the best of science to patients and their families,” said Jay Lombard, DO, Chief Scientific Officer and Medical Director for Genomind. “Despite the availability of a broad array of antidepressants, studies have shown that two-thirds of individuals with major depressive disorder fail to remit with an initial antidepressant trial of adequate dose and duration, and approximately half of this group fail to reach remission even with up to three more interventions. The Genecept Assay is available to clinicians and can help them more fully understand their patient’s genotype and assist in understanding potential responses to types of medications.”

“I put this seminar together to expose the NAMI membership to some creative ideas that are not mainstream in our field. We need to know how to use existing treatments better and these presenters and speakers will help us go forward,” said Kenneth M. Duckworth, MD, Medical Director for NAMI.

About Genomind, LLC: Genomind, LLC is a company specializing in neuropsychiatric personalized medicine and was formed to facilitate the adoption of Personalized Medicine into psychiatry by providing genetic information to better understand the patient. Genomind was founded by Ronald I Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health and bringing innovations in science, delivery, and access to mental health patients. He also is founder of ValueOptions, one of the nation’s leading behavioral health and wellness companies. Dr Jay Lombard, a neurologist, is co-founder of Genomind and is a nationally recognized leader in neuropsychiatry practice, research, and thought leadership. They are supported in their work by a Scientific Advisory Board comprised of internationally recognized researchers and thought leaders in psychiatry and neurology. Learn more at www.genomind.com.

About NAMI; NAMI is the National Alliance on Mental Illness, the nation’s largest grassroots organization dedicated to improving the lives of individuals and families affected by mental illness. NAMI has a national organization as well as state organizations and local affiliates in more than 1,100 communities across the country. More information can be found at: www.nami.org.

For more information, contact:

Adam Shapiro
ASPR
202-427-3603
Adam.Shapiro@ASPR.bz

Amy Pressman
Marketing Manager, Genomind
267-532-8866
apressman@genomind.com